OncLive.com· @OncLive · X·· 16 小时前评分70
正文 · 原文
📈 Significant PFS improvements were shown with iza-bren vs chemotherapy in pretreated HR+/HER2– advanced breast cancer, according to new data from the phase 3 PANKU-Breast01 trial
Read more here ➡️: https://www.onclive.com/view/panku-breast01-iza-bren-improves-pfs-vs-chemotherapy-pretreated-hr-her2-advanced-breast-cancer
#bcsm #oncology #ESMO26 @myESMO
107 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：OncLive.com · x.com